Monte Rosa Therapeutics Inc (GLUE) — Cash Flow Reinvestment Rate

Latest as of September 2025: 0.39x

Monte Rosa Therapeutics Inc (GLUE) has a Cash Flow Reinvestment Rate of 0.39x as of September 2025, reinvesting $38.79 Million (capex $651.00K plus investments $38.14 Million) from operating cash flow of $100.43 Million. Explore Monte Rosa Therapeutics Inc capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.39x
(Capex + Investments) / Operating CF

Total Reinvested

$38.79 Million
Capex + Investments

Operating Cash Flow

$100.43 Million
USD

Capital Expenditures

$651.00K
USD

Monte Rosa Therapeutics Inc Cash Flow Reinvestment Rate (2024–2024)

Historical reinvestment intensity for Monte Rosa Therapeutics Inc across 1 annual periods. Also explore Monte Rosa Therapeutics Inc (GLUE) total assets for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Monte Rosa Therapeutics Inc (2024–2024)

Year-by-year capital reinvestment analysis for Monte Rosa Therapeutics Inc. For live market cap and broader valuation context, see Monte Rosa Therapeutics Inc market cap and net worth.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2024 1.15x $48.44 Million $42.00 Million $3.99 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow